689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Silvio Danese(IRCCS Ospedale San Raffaele), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Hongyan Zhang(Tianjin University), Christopher O’Brien(Janssen (United States)), Thomas Baker(Janssen (United States)), María T. Abreu(Icahn School of Medicine at Mount Sinai), Jewel Johanns(Johnson & Johnson (United States)), Rupert W. Leong(The University of Sydney)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k